Wang Ming-Xuan, Deng Xiao-Long, Mu Bing-Yao, Cheng Yong-Jing, Chen Ying-Juan, Wang Qian, Huang Jia, Zhou Rong-Wei, Huang Ci-Bo
Department of Emergency Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Department of Neurology, Wuhan Medical & Healthcare Center for Women and Children, Wuhan Children's Hospital, Wuhan, Hubei, China.
Intern Emerg Med. 2016 Sep;11(6):867-76. doi: 10.1007/s11739-016-1496-5. Epub 2016 Jul 4.
Randomized, controlled trials (RCTs) have assessed the effect of colchicine therapy in prevention of pericardial effusion (PE) and atrial fibrillation (AF). However, the effects are still inconclusive. PubMed, Cochrane Library, Google Scholar, and EMBASE database were searched. Primary outcome was the risk of PE and AF. Ten RCTs with 1981 patients and a mean follow-up of 12.6 months were included. Colchicine therapy was not associated with a significantly lower risk of post-operative PE (RR, 0.89; 95 % CI 0.70-1.13; p = 0.33, I (2) = 72.8 %) and AF (RR, 0.77; 95 % CI 0.52-1.13; p = 0.18, I (2) = 47.3 %). However, rates of pericarditis recurrence, symptoms persistence, and pericarditis-related hospitalization were significantly decreased with colchicine treatment. In addition, cardiac tamponade occurrence was similar between groups, and adverse events were significantly higher in the colchicine group. Colchicine may not significantly decrease the post-operative risk of PE and AF. However, only limited studies about patients undergoing cardiac surgery provide data about PE and AF.
随机对照试验（RCT）已评估了秋水仙碱疗法在预防心包积液（PE）和心房颤动（AF）方面的效果。然而，其效果仍不明确。我们检索了PubMed、Cochrane图书馆、谷歌学术和EMBASE数据库。主要结局是发生PE和AF的风险。纳入了10项随机对照试验，共1981例患者，平均随访12.6个月。秋水仙碱疗法与术后PE风险显著降低无关（风险比，0.89；95%置信区间0.70 - 1.13；p = 0.33，I² = 72.8%），与AF风险显著降低也无关（风险比，0.77；95%置信区间0.52 - 1.13；p = 0.18，I² = 47.3%）。然而，秋水仙碱治疗可显著降低心包炎复发率、症状持续时间以及与心包炎相关的住院率。此外，两组间心脏压塞的发生率相似，且秋水仙碱组的不良事件显著更多。秋水仙碱可能不会显著降低术后PE和AF的风险。然而，关于心脏手术患者的研究有限，仅提供了有关PE和AF的数据。
